[
  {
    "title": "泽璟制药(688266.SH)：收到盐酸杰克替尼片注册现场核查和临床试验数据核查通知",
    "href": "http://stock.jrj.com.cn/2023/01/03164737255557.shtml",
    "datetime": "2023-01-03 16:47:26",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：控股股东及其一致行动人等自愿延长限售股锁定期12个月",
    "href": "http://stock.jrj.com.cn/2022/11/23174637161230.shtml",
    "datetime": "2022-11-23 17:46:13",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：向特定对象发行股票申请获得证监会同意注册批复",
    "href": "http://stock.jrj.com.cn/2022/11/13161437134454.shtml",
    "datetime": "2022-11-13 16:14:43",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)第三季度净亏损1.17亿元",
    "href": "http://stock.jrj.com.cn/2022/10/27165737089959.shtml",
    "datetime": "2022-10-27 16:57:09",
    "code": "688266"
  },
  {
    "title": "A股异动 | 泽璟制药-U涨10% 盐酸杰克替尼片新药上市申请获受理",
    "href": "http://stock.jrj.com.cn/2022/10/17101437059459.shtml",
    "datetime": "2022-10-17 10:14:18",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：披露盐酸杰克替尼片治疗中、高危骨髓纤维化III期临床试验主要数据",
    "href": "http://stock.jrj.com.cn/2022/10/17092637059247.shtml",
    "datetime": "2022-10-17 09:26:46",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266)：自愿披露递交盐酸杰克替尼片新药上市申请。",
    "href": "http://stock.jrj.com.cn/2022/09/29085537029799.shtml",
    "datetime": "2022-09-29 08:55:34",
    "code": "688266"
  },
  {
    "title": "国产首个JAK抑制剂申请上市 泽璟制药逐步实现多产品商业化",
    "href": "http://stock.jrj.com.cn/2022/09/28204837029069.shtml",
    "datetime": "2022-09-28 20:48:39",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：盐酸杰克替尼片已递交新药上市申请",
    "href": "http://stock.jrj.com.cn/2022/09/28160037027671.shtml",
    "datetime": "2022-09-28 16:00:19",
    "code": "688266"
  },
  {
    "title": "泽璟制药向特定对象发行股票获上交所审核通过",
    "href": "http://stock.jrj.com.cn/2022/09/28100037026846.shtml",
    "datetime": "2022-09-28 10:00:48",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：盐酸杰克替尼片用于治疗系统性红斑狼疮的临床试验获得批准",
    "href": "http://stock.jrj.com.cn/2022/09/21170037011434.shtml",
    "datetime": "2022-09-21 17:00:57",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：盐酸杰克替尼片用于治疗活动性强直性脊柱炎II期临床试验取得成功",
    "href": "http://stock.jrj.com.cn/2022/09/14165936994364.shtml",
    "datetime": "2022-09-14 16:59:14",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266)：自愿披露盐酸杰克替尼片临床试验申请获得FDA批准",
    "href": "http://stock.jrj.com.cn/2022/09/05091936972571.shtml",
    "datetime": "2022-09-05 09:19:38",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：盐酸杰克替尼片临床试验申请获得FDA批准",
    "href": "http://stock.jrj.com.cn/2022/09/04160736971909.shtml",
    "datetime": "2022-09-04 16:07:36",
    "code": "688266"
  },
  {
    "title": "泽璟制药2022年上半年亏损2.47亿 同比亏损增加 研发支出较大",
    "href": "http://stock.jrj.com.cn/2022/08/19115036915411.shtml",
    "datetime": "2022-08-19 11:50:08",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)半年度净亏损2.47亿元、同比扩大",
    "href": "http://stock.jrj.com.cn/2022/08/18172436912435.shtml",
    "datetime": "2022-08-18 17:24:43",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：注射用ZGGS18用于治疗晚期实体瘤的临床试验获批",
    "href": "http://stock.jrj.com.cn/2022/08/16155036904400.shtml",
    "datetime": "2022-08-16 15:50:27",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266)：自愿披露甲苯磺酸多纳非尼片新适应症上市申请获得批准",
    "href": "http://stock.jrj.com.cn/2022/08/15091136898757.shtml",
    "datetime": "2022-08-15 09:11:49",
    "code": "688266"
  },
  {
    "title": "泽璟制药：多纳非尼新适应症获批上市 覆盖患者群体进一步扩大",
    "href": "http://stock.jrj.com.cn/2022/08/14162736897804.shtml",
    "datetime": "2022-08-14 16:27:39",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：甲苯磺酸多纳非尼片新适应症上市申请获批",
    "href": "http://stock.jrj.com.cn/2022/08/14153636897720.shtml",
    "datetime": "2022-08-14 15:36:08",
    "code": "688266"
  },
  {
    "title": "泽璟制药：盐酸杰克替尼片又一临床试验取得成功 公司将加快推进其上市进程",
    "href": "http://stock.jrj.com.cn/2022/08/03205136868176.shtml",
    "datetime": "2022-08-03 20:51:36",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：盐酸杰克替尼片用于芦可替尼不耐受的中、高危骨髓纤维化患者的IIB期临床试验取得成功",
    "href": "http://stock.jrj.com.cn/2022/08/03165836867056.shtml",
    "datetime": "2022-08-03 16:58:47",
    "code": "688266"
  },
  {
    "title": "泽璟制药：ZGGS18临床试验申请获得FDA批准",
    "href": "http://stock.jrj.com.cn/2022/07/25154236839935.shtml",
    "datetime": "2022-07-25 15:42:31",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：用于治疗晚期实体瘤的ZGGS18临床试验申请获得FDA批准",
    "href": "http://stock.jrj.com.cn/2022/07/25153936839904.shtml",
    "datetime": "2022-07-25 15:39:50",
    "code": "688266"
  },
  {
    "title": "是否存在募投项目实施重大不确定性风险？泽璟制药回复问询函",
    "href": "http://stock.jrj.com.cn/2022/07/25142836839743.shtml",
    "datetime": "2022-07-25 14:28:11",
    "code": "688266"
  },
  {
    "title": "泽璟制药9名高管合计增持53.18万股 耗资1888.68万 2022年第一季度公司亏损1.19亿",
    "href": "http://stock.jrj.com.cn/2022/07/19223036826577.shtml",
    "datetime": "2022-07-19 22:30:32",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：“新药研发生产中心二期工程建设项目”延期",
    "href": "http://stock.jrj.com.cn/2022/07/19190736825985.shtml",
    "datetime": "2022-07-19 19:07:49",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：实控人、部分董事和高管及核心管理人员已完成增持计划、累计增持53.177万股",
    "href": "http://stock.jrj.com.cn/2022/07/19185436825957.shtml",
    "datetime": "2022-07-19 18:54:19",
    "code": "688266"
  },
  {
    "title": "泽璟制药：仑伐替尼和仿制药进入集采不会对销售业绩产生重大影响",
    "href": "http://stock.jrj.com.cn/2022/07/12134536803002.shtml",
    "datetime": "2022-07-12 13:45:25",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：就申请向特定对象发行股票、收到审核问询函",
    "href": "http://stock.jrj.com.cn/2022/06/23162336753313.shtml",
    "datetime": "2022-06-23 16:23:57",
    "code": "688266"
  },
  {
    "title": "泽璟制药盐酸杰克替尼片治疗中高危骨髓纤维化III临床试验期中分析达到试验主要终点",
    "href": "http://stock.jrj.com.cn/2022/06/22114636749061.shtml",
    "datetime": "2022-06-22 11:46:44",
    "code": "688266"
  },
  {
    "title": "泽璟制药：盐酸杰克替尼片首个III期临床研究成功 将加快推进其上市进程",
    "href": "http://stock.jrj.com.cn/2022/06/21215036747933.shtml",
    "datetime": "2022-06-21 21:50:07",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：盐酸杰克替尼片治疗中、高危骨髓纤维化III期临床试验期中分析达到试验主要终点",
    "href": "http://stock.jrj.com.cn/2022/06/21170236746649.shtml",
    "datetime": "2022-06-21 17:02:53",
    "code": "688266"
  },
  {
    "title": "泽璟制药：盐酸杰克替尼片用于治疗重型新型冠状病毒肺炎患者的临床试验获批",
    "href": "http://stock.jrj.com.cn/2022/06/15210736732635.shtml",
    "datetime": "2022-06-15 21:07:36",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：2021年度向特定对象发行A股股票申请获上交所受理",
    "href": "http://stock.jrj.com.cn/2022/06/09194636717033.shtml",
    "datetime": "2022-06-09 19:46:10",
    "code": "688266"
  },
  {
    "title": "泽璟制药“老药新用”角逐新冠药，为定增“造势”？",
    "href": "http://stock.jrj.com.cn/2022/06/05124536703398.shtml",
    "datetime": "2022-06-05 12:45:10",
    "code": "688266"
  },
  {
    "title": "业绩亏损扩大、年内股价腰斩，泽璟制药新冠药利好消息刺激能否持久？",
    "href": "http://stock.jrj.com.cn/2022/06/02110336699616.shtml",
    "datetime": "2022-06-02 11:03:38",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：已于近日启动盐酸杰克替尼片治疗中、重度特应性皮炎III期临床试验",
    "href": "http://stock.jrj.com.cn/2022/06/01180236697607.shtml",
    "datetime": "2022-06-01 18:02:52",
    "code": "688266"
  },
  {
    "title": "A股异动 | 泽璟制药(688266.SH)涨停 盐酸杰克替尼片临床试验申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/06/01144536696611.shtml",
    "datetime": "2022-06-01 14:45:27",
    "code": "688266"
  },
  {
    "title": "泽璟制药盐酸杰克替尼片临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2022/06/01111836696060.shtml",
    "datetime": "2022-06-01 11:18:59",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：盐酸杰克替尼片临床试验申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/05/31191636694226.shtml",
    "datetime": "2022-05-31 19:16:46",
    "code": "688266"
  },
  {
    "title": "泽璟制药（688266）：于电话会议、上证路演中心等举行投资者关系活动",
    "href": "http://stock.jrj.com.cn/2022/05/31082536691729.shtml",
    "datetime": "2022-05-31 08:25:57",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：外用重组人凝血酶生物制品上市许可申请获受理",
    "href": "http://stock.jrj.com.cn/2022/05/25183736678402.shtml",
    "datetime": "2022-05-25 18:37:24",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：A股定增募资规模拟由不超28.63亿元降至不超14.55亿元",
    "href": "http://stock.jrj.com.cn/2022/05/19205536663620.shtml",
    "datetime": "2022-05-19 20:55:30",
    "code": "688266"
  },
  {
    "title": "泽璟制药2022年第一季度亏损1.19亿同比亏损增加 研发支出增加",
    "href": "http://stock.jrj.com.cn/2022/05/04115036554807.shtml",
    "datetime": "2022-05-04 11:50:56",
    "code": "688266"
  },
  {
    "title": "泽璟制药2021年亏损4.51亿同比亏损增加 董事长盛泽林薪酬193.88万",
    "href": "http://stock.jrj.com.cn/2022/04/27221036486884.shtml",
    "datetime": "2022-04-27 22:10:04",
    "code": "688266"
  },
  {
    "title": "泽璟制药披露2021年年报 实现营收1.90亿元",
    "href": "http://stock.jrj.com.cn/2022/04/27104736482165.shtml",
    "datetime": "2022-04-27 10:47:24",
    "code": "688266"
  },
  {
    "title": "一图读财报：泽璟制药2021年营收同比大增近6倍 在研药品取得多项里程碑进展",
    "href": "http://stock.jrj.com.cn/2022/04/26225436479582.shtml",
    "datetime": "2022-04-26 22:54:45",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：实控人、部分董事和高管及核心管理人员拟合计增持1880万元-2370万元的股份",
    "href": "http://stock.jrj.com.cn/2022/03/02182234513002.shtml",
    "datetime": "2022-03-02 18:22:32",
    "code": "688266"
  },
  {
    "title": "泽璟制药2021年亏损4.14亿同比亏损增加 新药研发投入增加较多",
    "href": "http://stock.jrj.com.cn/2022/02/23203034447871.shtml",
    "datetime": "2022-02-23 20:30:08",
    "code": "688266"
  },
  {
    "title": "泽璟制药：KRAS突变肿瘤治疗将迎来新突破 未来有望进一步造福患者",
    "href": "http://stock.jrj.com.cn/2022/02/17101634380952.shtml",
    "datetime": "2022-02-17 10:16:37",
    "code": "688266"
  },
  {
    "title": "泽璟制药-U：产品线暗忧浮现",
    "href": "http://stock.jrj.com.cn/2022/02/16095634363909.shtml",
    "datetime": "2022-02-16 09:56:03",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：588.51万股限售股将于2月23日解禁上市",
    "href": "http://stock.jrj.com.cn/2022/02/14165334344980.shtml",
    "datetime": "2022-02-14 16:53:20",
    "code": "688266"
  },
  {
    "title": "泽璟制药2021年预计亏损3.72亿-4.55亿 研发支出进一步增加",
    "href": "http://stock.jrj.com.cn/2022/01/28201034248451.shtml",
    "datetime": "2022-01-28 20:10:52",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：2021年度预亏3.72亿元-4.55亿元",
    "href": "http://stock.jrj.com.cn/2022/01/28173234243406.shtml",
    "datetime": "2022-01-28 17:32:45",
    "code": "688266"
  },
  {
    "title": "泽璟制药：ZG19018片临床试验申请获得FDA批准",
    "href": "http://stock.jrj.com.cn/2022/01/23160534194226.shtml",
    "datetime": "2022-01-23 16:05:31",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：ZG19018片临床试验申请获得FDA批准",
    "href": "http://stock.jrj.com.cn/2022/01/23155034194201.shtml",
    "datetime": "2022-01-23 15:50:41",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：小核酸研究所拟无偿划转2.88%股份至昆山工研院",
    "href": "http://stock.jrj.com.cn/2022/01/21155834182551.shtml",
    "datetime": "2022-01-21 15:58:26",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：ZG005粉针剂临床试验申请获得FDA批准",
    "href": "http://stock.jrj.com.cn/2022/01/20161534178629.shtml",
    "datetime": "2022-01-20 16:15:32",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：拟使用不超9亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/01/19192234175228.shtml",
    "datetime": "2022-01-19 19:22:21",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：子公司香港泽璟拟收购GENSUN经完全摊薄后4%股份",
    "href": "http://stock.jrj.com.cn/2022/01/19184934175122.shtml",
    "datetime": "2022-01-19 18:49:12",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：180万股限售股将于1月24日解禁上市",
    "href": "http://stock.jrj.com.cn/2022/01/13172234154574.shtml",
    "datetime": "2022-01-13 17:22:19",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：ZG005粉针剂用于治疗实体瘤患者的临床试验获得批准",
    "href": "http://stock.jrj.com.cn/2021/12/30161734086920.shtml",
    "datetime": "2021-12-30 16:17:58",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：ZG19018片治疗KRASG12C突变的晚期恶性实体瘤的临床试验获得批准",
    "href": "http://stock.jrj.com.cn/2021/12/28162534076480.shtml",
    "datetime": "2021-12-28 16:25:31",
    "code": "688266"
  },
  {
    "title": "泽璟制药：甲苯磺酸多纳非尼片纳入2021年国家医保药品目录",
    "href": "http://stock.jrj.com.cn/2021/12/03155633960170.shtml",
    "datetime": "2021-12-03 15:56:33",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：甲苯磺酸多纳非尼片纳入国家医保目录",
    "href": "http://stock.jrj.com.cn/2021/12/03154233960081.shtml",
    "datetime": "2021-12-03 15:42:51",
    "code": "688266"
  },
  {
    "title": "泽璟制药：拟定增募资不超过28.6亿元",
    "href": "http://stock.jrj.com.cn/2021/11/25165833919258.shtml",
    "datetime": "2021-11-25 16:58:37",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：拟定增募资不超28.63亿元 用于新药研发项目等",
    "href": "http://stock.jrj.com.cn/2021/11/25165833919260.shtml",
    "datetime": "2021-11-25 16:58:34",
    "code": "688266"
  },
  {
    "title": "泽璟制药：多纳非尼百余天销售额近1亿元 公司商业化能力初步得到市场验证",
    "href": "http://stock.jrj.com.cn/2021/10/26184933756560.shtml",
    "datetime": "2021-10-26 18:49:56",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：第三季度净亏损1.16亿元",
    "href": "http://stock.jrj.com.cn/2021/10/26160333754635.shtml",
    "datetime": "2021-10-26 16:03:59",
    "code": "688266"
  },
  {
    "title": "A股异动 | 泽璟制药(688266.SH)涨4% ZG005粉针剂临床试验申请获得受理",
    "href": "http://stock.jrj.com.cn/2021/10/25101033745675.shtml",
    "datetime": "2021-10-25 10:10:52",
    "code": "688266"
  },
  {
    "title": "泽璟制药：ZG005粉针剂临床试验申请获得受理",
    "href": "http://stock.jrj.com.cn/2021/10/24154433739347.shtml",
    "datetime": "2021-10-24 15:44:23",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：甲苯磺酸多纳非尼片新适应症上市申请获得受理",
    "href": "http://stock.jrj.com.cn/2021/10/18142733710396.shtml",
    "datetime": "2021-10-18 14:27:26",
    "code": "688266"
  },
  {
    "title": "泽璟制药2021年半年度亏损1.77亿元 同比亏损增加",
    "href": "http://stock.jrj.com.cn/2021/08/25162433316670.shtml",
    "datetime": "2021-08-25 16:24:55",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：上半年净亏损1.77亿元",
    "href": "http://stock.jrj.com.cn/2021/08/25160633316538.shtml",
    "datetime": "2021-08-25 16:06:14",
    "code": "688266"
  },
  {
    "title": "泽璟制药布局甲状腺癌治疗领域 年内将提交泽普生治疗RAIR-DTC适应症上市申请",
    "href": "http://stock.jrj.com.cn/2021/08/18144933273716.shtml",
    "datetime": "2021-08-18 14:49:53",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：甲苯磺酸多纳非尼片治疗二线以上晚期结直肠癌Ⅲ期临床试验未达到预设目标",
    "href": "http://stock.jrj.com.cn/2021/08/16180333261518.shtml",
    "datetime": "2021-08-16 18:03:17",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：多纳非尼治疗碘难治性分化型甲状腺癌Ⅲ期临床试验期中分析提前达到试验终点",
    "href": "http://stock.jrj.com.cn/2021/08/16180033261484.shtml",
    "datetime": "2021-08-16 18:00:25",
    "code": "688266"
  },
  {
    "title": "秃头者福音？泽璟制药启动盐酸杰克替尼片治疗重症斑秃Ⅲ期临床试验",
    "href": "http://stock.jrj.com.cn/2021/07/01095233026340.shtml",
    "datetime": "2021-07-01 09:52:32",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：将启动盐酸杰克替尼片治疗重症斑秃Ⅲ期临床试验",
    "href": "http://stock.jrj.com.cn/2021/06/30171533022283.shtml",
    "datetime": "2021-06-30 17:15:52",
    "code": "688266"
  },
  {
    "title": "斑秃患者的希望 泽璟制药盐酸杰克替尼片治疗重症斑秃II期临床研究取得成功",
    "href": "http://stock.jrj.com.cn/2021/06/29083733014065.shtml",
    "datetime": "2021-06-29 08:37:13",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：盐酸杰克替尼片治疗重症斑秃II期临床试验取得成功结果",
    "href": "http://stock.jrj.com.cn/2021/06/28172333010706.shtml",
    "datetime": "2021-06-28 17:23:19",
    "code": "688266"
  },
  {
    "title": "泽璟制药：外用重组人凝血酶的III期临床试验目前进展顺利",
    "href": "http://stock.jrj.com.cn/2021/06/24112432988519.shtml",
    "datetime": "2021-06-24 11:24:43",
    "code": "688266"
  },
  {
    "title": "泽璟制药：外用重组人凝血酶的III期临床试验目前正在进行中",
    "href": "http://stock.jrj.com.cn/2021/06/18183132955806.shtml",
    "datetime": "2021-06-18 18:31:33",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：将于EHA大会口头公布盐酸杰克替尼片治疗中、高危骨髓纤维化II期临床试验数据",
    "href": "http://stock.jrj.com.cn/2021/06/10172932905777.shtml",
    "datetime": "2021-06-10 17:29:58",
    "code": "688266"
  },
  {
    "title": "泽璟制药：甲苯磺酸多纳非尼片获批上市",
    "href": "http://stock.jrj.com.cn/2021/06/10090732903581.shtml",
    "datetime": "2021-06-10 09:07:45",
    "code": "688266"
  },
  {
    "title": "泽璟制药：首个中国自主研发肝癌一线优效靶向药多纳非尼片（泽普生）获批上市",
    "href": "http://stock.jrj.com.cn/2021/06/10080032903529.shtml",
    "datetime": "2021-06-10 08:00:21",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：甲苯磺酸多纳非尼片获批上市",
    "href": "http://stock.jrj.com.cn/2021/06/09154232899765.shtml",
    "datetime": "2021-06-09 15:42:40",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)向212名激励对象首次授予192万股限制性股票",
    "href": "http://stock.jrj.com.cn/2021/06/01170932857533.shtml",
    "datetime": "2021-06-01 17:09:31",
    "code": "688266"
  },
  {
    "title": "泽璟制药：向激励对象首次授予限制性股票",
    "href": "http://stock.jrj.com.cn/2021/06/01164632857295.shtml",
    "datetime": "2021-06-01 16:46:49",
    "code": "688266"
  },
  {
    "title": "泽璟制药：目前多纳非尼结直肠癌的Ⅲ期临床试验在数据清理及进行研究中心质控阶段",
    "href": "http://stock.jrj.com.cn/2021/05/13155232748470.shtml",
    "datetime": "2021-05-13 15:52:34",
    "code": "688266"
  },
  {
    "title": "泽璟制药：目前多纳非尼原料药和片剂已经完成了注册检验、二合一检查和临床核查 进入了综合审评阶段",
    "href": "http://stock.jrj.com.cn/2021/05/13154932748461.shtml",
    "datetime": "2021-05-13 15:49:32",
    "code": "688266"
  },
  {
    "title": "泽璟制药2020年亏损3.19亿 董事长盛泽林薪酬173.11万",
    "href": "http://stock.jrj.com.cn/2021/04/29141832479647.shtml",
    "datetime": "2021-04-29 14:18:43",
    "code": "688266"
  },
  {
    "title": "亏亏亏！去年亏超3亿元 泽璟制药何时可以实现盈利？",
    "href": "http://stock.jrj.com.cn/2021/04/29113832478986.shtml",
    "datetime": "2021-04-29 11:38:07",
    "code": "688266"
  },
  {
    "title": "泽璟制药：近日将启动rhTSHⅢ期临床试验",
    "href": "http://stock.jrj.com.cn/2021/03/02102532055834.shtml",
    "datetime": "2021-03-02 10:25:30",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)拟启动rhTSHⅢ期临床试验",
    "href": "http://stock.jrj.com.cn/2021/03/01174032051235.shtml",
    "datetime": "2021-03-01 17:40:44",
    "code": "688266"
  },
  {
    "title": "泽璟制药2020年度亏损3.18亿同比亏损减少 公开发行新股募集资金到账",
    "href": "http://stock.jrj.com.cn/2021/02/25214032028014.shtml",
    "datetime": "2021-02-25 21:40:44",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)业绩快报：2020年度净亏损3.18亿元",
    "href": "http://stock.jrj.com.cn/2021/02/25173732026574.shtml",
    "datetime": "2021-02-25 17:37:09",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：杰克替尼片治疗中、高危骨髓纤维化II期临床试验取得成功结果",
    "href": "http://stock.jrj.com.cn/2021/02/22170832006566.shtml",
    "datetime": "2021-02-22 17:08:36",
    "code": "688266"
  },
  {
    "title": "泽璟制药2020年预计亏损2.95亿-3.38亿同比减亏26.73%到36.23% 取得授权许可收入",
    "href": "http://stock.jrj.com.cn/2021/01/28230231803817.shtml",
    "datetime": "2021-01-28 23:02:04",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：7483.32万股限售股1月25日解禁",
    "href": "http://stock.jrj.com.cn/2021/01/14171831692445.shtml",
    "datetime": "2021-01-14 17:18:56",
    "code": "688266"
  },
  {
    "title": "[泽璟制药]泽璟制药启动盐酸杰克替尼片治疗中高危骨髓纤维化的Ⅲ期临床试验",
    "href": "http://stock.jrj.com.cn/2021/01/12000031681028.shtml",
    "datetime": "2021-01-12 00:00:00",
    "code": "688266"
  },
  {
    "title": "泽璟制药：目前盐酸杰克替尼片正在开展多个适应症的临床试验",
    "href": "http://stock.jrj.com.cn/2021/01/11181431671436.shtml",
    "datetime": "2021-01-11 18:14:23",
    "code": "688266"
  },
  {
    "title": "泽璟制药：赶上时代红利，输给“拖延症”",
    "href": "http://stock.jrj.com.cn/2020/12/30195631606628.shtml",
    "datetime": "2020-12-30 19:56:00",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：收到甲苯磺酸多纳非尼片药品注册现场核查通知",
    "href": "http://stock.jrj.com.cn/2020/12/30175031605676.shtml",
    "datetime": "2020-12-30 17:50:07",
    "code": "688266"
  },
  {
    "title": "泽璟制药：多纳非尼正在和多个抗肿瘤免疫治疗药物包括抗PD-1/L1抗体进行联合治疗的临床试验",
    "href": "http://stock.jrj.com.cn/2020/12/17153831509520.shtml",
    "datetime": "2020-12-17 15:38:14",
    "code": "688266"
  },
  {
    "title": "泽璟制药：在研产品获美国FDA孤儿药资格认定",
    "href": "http://stock.jrj.com.cn/2020/12/17101831508016.shtml",
    "datetime": "2020-12-17 10:18:49",
    "code": "688266"
  },
  {
    "title": "[泽璟制药]泽璟制药盐酸杰克替尼片获得FDA孤儿药资格认定",
    "href": "http://stock.jrj.com.cn/2020/12/17000031507934.shtml",
    "datetime": "2020-12-17 00:00:00",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：在研产品盐酸杰克替尼片获得FDA孤儿药资格认定",
    "href": "http://stock.jrj.com.cn/2020/12/16173031503194.shtml",
    "datetime": "2020-12-16 17:30:46",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)：索拉非尼口服常释剂型(规格0.2g)纳入集中采购品种范围",
    "href": "http://stock.jrj.com.cn/2020/12/14150031486653.shtml",
    "datetime": "2020-12-14 15:00:01",
    "code": "688266"
  },
  {
    "title": "泽璟制药(688266.SH)需向CDE递交研究资料说明及补充资料",
    "href": "http://stock.jrj.com.cn/2020/12/13190131476595.shtml",
    "datetime": "2020-12-13 19:01:46",
    "code": "688266"
  },
  {
    "title": "泽璟制药：索拉非尼纳入集采 预计对其未来市场份额及定价产生一定程度的影响",
    "href": "http://stock.jrj.com.cn/kcb/2020/12/13161431475844.shtml",
    "datetime": "2020-12-13 16:14:45",
    "code": "688266"
  },
  {
    "title": "泽璟制药：公司已经开展除了氘代技术外的其他技术应用",
    "href": "http://stock.jrj.com.cn/2020/12/07183131432108.shtml",
    "datetime": "2020-12-07 18:31:54",
    "code": "688266"
  },
  {
    "title": "[泽璟制药]泽璟制药奥贝胆酸镁片获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2020/11/17000031306595.shtml",
    "datetime": "2020-11-17 00:00:00",
    "code": "688266"
  },
  {
    "title": "泽璟制药前三季度亏损2.28亿 研发费用同比增长",
    "href": "http://stock.jrj.com.cn/2020/10/31133931180982.shtml",
    "datetime": "2020-10-31 13:39:27",
    "code": "688266"
  },
  {
    "title": "泽璟制药：2020年前三季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/10/30011031162912.shtml",
    "datetime": "2020-10-30 01:10:15",
    "code": "688266"
  },
  {
    "title": "科创50指数样本首次调整 优刻得、泽璟制药等5只证券调入指数",
    "href": "http://stock.jrj.com.cn/2020/08/28172130615056.shtml",
    "datetime": "2020-08-28 17:21:55",
    "code": "688266"
  },
  {
    "title": "泽璟制药2020年上半年亏损1.29亿亏损减少 各项新药研发项目持续推进",
    "href": "http://stock.jrj.com.cn/2020/08/17232230522139.shtml",
    "datetime": "2020-08-17 23:22:47",
    "code": "688266"
  },
  {
    "title": "科创板泽璟制药：上半年亏损1.29亿元",
    "href": "http://stock.jrj.com.cn/kcb/2020/08/16142530506607.shtml",
    "datetime": "2020-08-16 14:25:21",
    "code": "688266"
  },
  {
    "title": "新药面临“前后夹击” 泽璟制药“自我造血”需待何时？",
    "href": "http://stock.jrj.com.cn/kcb/2020/08/05082230429139.shtml",
    "datetime": "2020-08-05 08:22:20",
    "code": "688266"
  },
  {
    "title": "泽璟制药开出未盈利上市药方 首创以可比估值指标定发行价",
    "href": "http://stock.jrj.com.cn/2020/07/20023530284908.shtml",
    "datetime": "2020-07-20 02:35:29",
    "code": "688266"
  },
  {
    "title": "泽璟制药聘任张均利为公司副总经理",
    "href": "http://stock.jrj.com.cn/2020/07/16194730263413.shtml",
    "datetime": "2020-07-16 19:47:40",
    "code": "688266"
  },
  {
    "title": "泽璟制药召开2019年度业绩说明会 董事长盛泽林：下半年会完成营销队伍建设",
    "href": "http://stock.jrj.com.cn/2020/05/26171829769161.shtml",
    "datetime": "2020-05-26 17:18:52",
    "code": "688266"
  },
  {
    "title": "泽璟制药：2019年年度股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2020/05/21074029727877.shtml",
    "datetime": "2020-05-21 07:40:02",
    "code": "688266"
  },
  {
    "title": "泽璟制药2020年第一季度亏损6226.29万 亏损减少",
    "href": "http://stock.jrj.com.cn/2020/05/01143029440105.shtml",
    "datetime": "2020-05-01 14:30:50",
    "code": "688266"
  },
  {
    "title": "泽璟制药2019年亏损4.62亿元 尚无药品上市销售",
    "href": "http://stock.jrj.com.cn/2020/04/28184929406687.shtml",
    "datetime": "2020-04-28 18:49:55",
    "code": "688266"
  },
  {
    "title": "泽璟制药：2019年年度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/04/28155029405107.shtml",
    "datetime": "2020-04-28 15:50:18",
    "code": "688266"
  },
  {
    "title": "泽璟制药：2020年第一季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/04/28155029405108.shtml",
    "datetime": "2020-04-28 15:50:18",
    "code": "688266"
  },
  {
    "title": "泽璟制药：第一届董事会第十四次会议决议公告",
    "href": "http://stock.jrj.com.cn/2020/04/28155029405109.shtml",
    "datetime": "2020-04-28 15:50:18",
    "code": "688266"
  },
  {
    "title": "泽璟制药：关于召开2019年年度股东大会的通知",
    "href": "http://stock.jrj.com.cn/2020/04/28155029405110.shtml",
    "datetime": "2020-04-28 15:50:18",
    "code": "688266"
  },
  {
    "title": "泽璟制药：抗肿瘤药物多纳非尼递交新药上市申请",
    "href": "http://stock.jrj.com.cn/2020/03/23185129085041.shtml",
    "datetime": "2020-03-23 18:51:46",
    "code": "688266"
  },
  {
    "title": "泽璟制药：盐酸杰克替尼片获准开展治疗中、重度特应性皮炎Ⅱ期临床试验",
    "href": "http://stock.jrj.com.cn/2020/03/17163929045121.shtml",
    "datetime": "2020-03-17 16:39:38",
    "code": "688266"
  },
  {
    "title": "泽璟制药：获得临床试验通知书",
    "href": "http://stock.jrj.com.cn/2020/03/17162129045003.shtml",
    "datetime": "2020-03-17 16:21:30",
    "code": "688266"
  },
  {
    "title": "泽璟制药：2020年第一次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2020/03/10000028983433.shtml",
    "datetime": "2020-03-10 00:00:13",
    "code": "688266"
  },
  {
    "title": "泽璟制药：获得临床试验通知书",
    "href": "http://stock.jrj.com.cn/2020/03/03210628947005.shtml",
    "datetime": "2020-03-03 21:06:00",
    "code": "688266"
  },
  {
    "title": "泽璟制药亏损扩大 18个交易日市值最高蒸发81亿元",
    "href": "http://stock.jrj.com.cn/2020/02/29093028918937.shtml",
    "datetime": "2020-02-29 09:30:00",
    "code": "688266"
  },
  {
    "title": "泽璟制药2019年亏损4.62亿 去年无药品上市销售",
    "href": "http://stock.jrj.com.cn/2020/02/28100628911934.shtml",
    "datetime": "2020-02-28 10:06:51",
    "code": "688266"
  },
  {
    "title": "泽璟制药：关于召开2020年第一次临时股东大会的通知",
    "href": "http://stock.jrj.com.cn/2020/02/21220028873789.shtml",
    "datetime": "2020-02-21 22:00:16",
    "code": "688266"
  },
  {
    "title": "科创板将迎来“第五套标准”上市第一股：泽璟制药",
    "href": "http://stock.jrj.com.cn/2020/01/22195828722563.shtml",
    "datetime": "2020-01-22 19:58:05",
    "code": "688266"
  },
  {
    "title": "无产品无收入无利润 泽璟制药拟发33.76元谁博傻接盘？",
    "href": "http://stock.jrj.com.cn/kcb/2020/01/21080828711118.shtml",
    "datetime": "2020-01-21 08:08:45",
    "code": "688266"
  },
  {
    "title": "泽璟制药IPO：网上中签号码3.44万个",
    "href": "http://stock.jrj.com.cn/2020/01/15230828683141.shtml",
    "datetime": "2020-01-15 23:08:08",
    "code": "688266"
  },
  {
    "title": "【兑奖啦】泽璟制药、有方科技、玉禾田网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2020/01/15205528682649.shtml",
    "datetime": "2020-01-15 20:55:53",
    "code": "688266"
  },
  {
    "title": "泽璟制药中签号出炉 共3.44万个",
    "href": "http://stock.jrj.com.cn/2020/01/15191028682328.shtml",
    "datetime": "2020-01-15 19:10:00",
    "code": "688266"
  },
  {
    "title": "1月15日新股提示：斯达半导申购 奥普家居上市 洁特生物中签号出炉 有方科技、泽璟制药、玉禾田公布中签率",
    "href": "http://stock.jrj.com.cn/ipo/2020/01/15091428678820.shtml",
    "datetime": "2020-01-15 09:14:31",
    "code": "688266"
  },
  {
    "title": "泽璟制药IPO：网上中签率0.05017704%",
    "href": "http://stock.jrj.com.cn/2020/01/14225628677527.shtml",
    "datetime": "2020-01-14 22:56:03",
    "code": "688266"
  },
  {
    "title": "玉禾田、泽璟制药、有方科技网上发行中签率出炉",
    "href": "http://stock.jrj.com.cn/ipo/2020/01/14213128677226.shtml",
    "datetime": "2020-01-14 21:31:02",
    "code": "688266"
  },
  {
    "title": "有方科技：网上发行最终中签率为0.04203630％",
    "href": "http://stock.jrj.com.cn/ipo/2020/01/14191328676701.shtml",
    "datetime": "2020-01-14 19:13:50",
    "code": "688266"
  },
  {
    "title": "泽璟制药：网上发行最终中签率为0.05017704％",
    "href": "http://stock.jrj.com.cn/ipo/2020/01/14191228676700.shtml",
    "datetime": "2020-01-14 19:12:24",
    "code": "688266"
  },
  {
    "title": "1月14日新股提示：有方科技、泽璟制药、玉禾田申购 万德斯、泰林生物上市 洁特生物公布中签率",
    "href": "http://stock.jrj.com.cn/ipo/2020/01/14084728672053.shtml",
    "datetime": "2020-01-14 08:47:07",
    "code": "688266"
  },
  {
    "title": "新股提示：玉禾田、泽璟制药、有方科技今日申购",
    "href": "http://stock.jrj.com.cn/2020/01/14072528671859.shtml",
    "datetime": "2020-01-14 07:25:00",
    "code": "688266"
  },
  {
    "title": "A股史上第一家：0营收、亏损10亿的企业 你会申购吗",
    "href": "http://stock.jrj.com.cn/2020/01/13204128669105.shtml",
    "datetime": "2020-01-13 20:41:56",
    "code": "688266"
  },
  {
    "title": "科创板新股泽璟制药、有方科技1月14日申购宝典",
    "href": "http://stock.jrj.com.cn/ipo/2020/01/13143128666883.shtml",
    "datetime": "2020-01-13 14:31:14",
    "code": "688266"
  },
  {
    "title": "A股首例未盈利企业IPO 泽璟制药定价成焦点",
    "href": "http://stock.jrj.com.cn/2020/01/13022628664090.shtml",
    "datetime": "2020-01-13 02:26:57",
    "code": "688266"
  },
  {
    "title": "泽璟制药确定发行价33.76元/股 承销商定价能力受考验",
    "href": "http://stock.jrj.com.cn/2020/01/12213228663870.shtml",
    "datetime": "2020-01-12 21:32:00",
    "code": "688266"
  },
  {
    "title": "科创板泽璟制药：发行价确定为33.76元/股",
    "href": "http://stock.jrj.com.cn/2020/01/12152528663378.shtml",
    "datetime": "2020-01-12 15:25:00",
    "code": "688266"
  },
  {
    "title": "未盈利企业泽璟制药率先圆梦科创板 掘金后肿瘤时代",
    "href": "http://stock.jrj.com.cn/kcb/2020/01/09033928646225.shtml",
    "datetime": "2020-01-09 03:39:55",
    "code": "688266"
  },
  {
    "title": "泽璟制药后备新药充足 外用重组人凝血酶计划2021年申请NDA",
    "href": "http://stock.jrj.com.cn/2020/01/08143028643186.shtml",
    "datetime": "2020-01-08 14:30:58",
    "code": "688266"
  },
  {
    "title": "泽璟制药布局第二代肿瘤免疫治疗领域",
    "href": "http://stock.jrj.com.cn/2020/01/07140228636833.shtml",
    "datetime": "2020-01-07 14:02:45",
    "code": "688266"
  },
  {
    "title": "泽璟制药启动IPO A股迎来首家未盈利企业",
    "href": "http://stock.jrj.com.cn/2020/01/07041228633848.shtml",
    "datetime": "2020-01-07 04:12:10",
    "code": "688266"
  },
  {
    "title": "A股新里程碑！首家未盈利企业启动IPO！业内人士称潮流不可逆",
    "href": "http://stock.jrj.com.cn/2020/01/06211428633132.shtml",
    "datetime": "2020-01-06 21:14:12",
    "code": "688266"
  },
  {
    "title": "小分子靶向创新药将步入黄金收获期 泽璟制药或将受益",
    "href": "http://stock.jrj.com.cn/2020/01/06101628629771.shtml",
    "datetime": "2020-01-06 10:16:29",
    "code": "688266"
  },
  {
    "title": "科创板拟上市公司泽璟制药提交注册",
    "href": "http://stock.jrj.com.cn/2019/12/31170728611500.shtml",
    "datetime": "2019-12-31 17:07:00",
    "code": "688266"
  },
  {
    "title": "上交所：聚辰股份、泽璟制药提交科创板注册",
    "href": "http://stock.jrj.com.cn/2019/11/04171128349153.shtml",
    "datetime": "2019-11-04 17:11:00",
    "code": "688266"
  },
  {
    "title": "首家采用第5套上市标准 亏损企业泽璟制药科创板过会",
    "href": "http://stock.jrj.com.cn/kcb/2019/11/01025528336099.shtml",
    "datetime": "2019-11-01 02:55:22",
    "code": "688266"
  },
  {
    "title": "“三无公司”泽璟制药科创板过会 政策红利能吃多久？",
    "href": "http://stock.jrj.com.cn/2019/11/01000828335893.shtml",
    "datetime": "2019-11-01 00:08:08",
    "code": "688266"
  },
  {
    "title": "泽璟制药过会 首家亏损上市企业来了",
    "href": "http://stock.jrj.com.cn/kcb/2019/10/31010828328954.shtml",
    "datetime": "2019-10-31 01:08:16",
    "code": "688266"
  },
  {
    "title": "科创板上市委：八亿时空、泽璟制药首发通过",
    "href": "http://stock.jrj.com.cn/2019/10/30194128327630.shtml",
    "datetime": "2019-10-30 19:41:00",
    "code": "688266"
  },
  {
    "title": "泽璟制药科创板IPO：突击收购实控人妹妹公司 上市前0.5折卖股损失3亿",
    "href": "http://stock.jrj.com.cn/2019/10/25165828300852.shtml",
    "datetime": "2019-10-25 16:58:39",
    "code": "688266"
  },
  {
    "title": "科创板上市委：八亿时空、泽璟制药首发定于10月30日上会",
    "href": "http://stock.jrj.com.cn/2019/10/21200728278576.shtml",
    "datetime": "2019-10-21 20:07:00",
    "code": "688266"
  },
  {
    "title": "泽璟制药完成首轮问询 盈利问题被关注",
    "href": "http://stock.jrj.com.cn/kcb/2019/08/08055827945167.shtml",
    "datetime": "2019-08-08 05:58:31",
    "code": "688266"
  },
  {
    "title": "泽璟制药：47亿与131万的反差",
    "href": "http://stock.jrj.com.cn/kcb/2019/07/08042927806685.shtml",
    "datetime": "2019-07-08 04:29:16",
    "code": "688266"
  },
  {
    "title": "唯一选择40亿的科创板申报企业泽璟制药 营收仅131万",
    "href": "http://stock.jrj.com.cn/kcb/2019/07/04204927798404.shtml",
    "datetime": "2019-07-04 20:49:03",
    "code": "688266"
  },
  {
    "title": "首个用第五套标准申报科创板的泽璟制药：3年亏7亿，你敢投资吗？",
    "href": "http://stock.jrj.com.cn/2019/06/13211027701385.shtml",
    "datetime": "2019-06-13 21:10:57",
    "code": "688266"
  },
  {
    "title": "只有它！首家科创板第五套标准企业获受理 拟募资23.84亿",
    "href": "http://stock.jrj.com.cn/2019/06/11011827682805.shtml",
    "datetime": "2019-06-11 01:18:00",
    "code": "688266"
  },
  {
    "title": "首家！泽璟制药选用科创板第五套上市标准",
    "href": "http://stock.jrj.com.cn/2019/06/10200427682042.shtml",
    "datetime": "2019-06-10 20:04:00",
    "code": "688266"
  },
  {
    "title": "泽璟制药科创板上市申请获受理",
    "href": "http://stock.jrj.com.cn/2019/06/10173027681441.shtml",
    "datetime": "2019-06-10 17:30:00",
    "code": "688266"
  }
]